Literature DB >> 22149551

Candesartan cilexetil in children and adolescents aged 1 to <17 years with hypertension: profile report.

Sheridan M Hoy1, Gillian M Keating.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22149551     DOI： 10.2165/11206950-000000000-00000

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN： 1174-5878            Impact factor:   3.022


× No keyword cloud information.
  7 in total

1.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

Review 2.  Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Am J Cardiovasc Drugs       Date:  2010       Impact factor: 3.571

3.  Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.

Authors:  Franz Schaefer; Johan van de Walle; Aleksandra Zurowska; Charlotte Gimpel; Koen van Hoeck; Dorota Drozdz; Giovanni Montini; Ingretta V Bagdasorova; Jonathan Sorof; Jennifer Sugg; Renli Teng; James W Hainer
Journal:  J Hypertens       Date:  2010-05       Impact factor: 4.844

4.  Underdiagnosis of hypertension in children and adolescents.

Authors:  Matthew L Hansen; Paul W Gunn; David C Kaelber
Journal:  JAMA       Date:  2007-08-22       Impact factor: 56.272

5.  Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension.

Authors:  Empar Lurbe; Renata Cifkova; J Kennedy Cruickshank; Michael J Dillon; Isabel Ferreira; Cecilia Invitti; Tatiana Kuznetsova; Stephane Laurent; Giuseppe Mancia; Francisco Morales-Olivas; Wolfgang Rascher; Josep Redon; Franz Schaefer; Tomas Seeman; George Stergiou; Elke Wühl; Alberto Zanchetti
Journal:  J Hypertens       Date:  2009-09       Impact factor: 4.844

Review 6.  Pediatric hypertension: recent trends and accomplishments, future challenges.

Authors:  Joseph T Flynn
Journal:  Am J Hypertens       Date:  2008-04-17       Impact factor: 2.689

7.  Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.

Authors:  Howard Trachtman; James W Hainer; Jennifer Sugg; Renli Teng; Jonathan M Sorof; Jerilynn Radcliffe
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-10       Impact factor: 3.738
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.